<DOC>
	<DOCNO>NCT00525161</DOCNO>
	<brief_summary>The purpose study determine clinical response rate sorafenib add exist endocrine therapy patient advance breast cancer .</brief_summary>
	<brief_title>Study Adding Multikinase Inhibitor Sorafenib Existing Endocrine Therapy Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>A pilot Phase II study add sorafenib endocrine therapy 11 patient metastatic estrogen receptor-positive breast cancer conduct . Primary end point response Response Evaluation Criteria Solid Tumors ( RECIST ) 3 month sorafenib . Secondary end point include safety , time progression biomarker modulation . The study close early owe slow accrual .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>All subject must female . Age ≥ 18 year old . Histologically proven carcinoma breast . Estrogen receptor and/or Progesterone positive disease . Metastatic locally advance disease . Patients preexist endocrine agent least 3 month enrollment . Have residual measurable disease 1. maximal response endocrine therapy 2. response endocrine therapy 3. progressive nonvisceral disease endocrine therapy . Must able provide tumor block either primary metastatic site , available . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . Adequate organ function . Patients rapidly progressive disease endocrine therapy would otherwise candidate chemotherapy . Other coexist malignancy , exception basal cell carcinoma cervical carcinoma situ . Prior use antiangiogenic agent . As judged investigator , uncontrolled intercurrent illness . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Treatment nonapproved investigational drug within 30 day Day 1 study treatment . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort . Known suspect allergy sorafenib agent give course trial . A serious nonhealing wound ulcer . Evidence history bleed diathesis coagulopathy . Major surgery , open biopsy significant traumatic injury within 4 week prior first dose study drug . Pulmonary hemorrhage/bleeding event ≥ Common Toxicity Criteria Adverse Effects ( CTCAE ) Grade 2 within 4 week prior first dose study drug . Pregnancy Any condition impair patient 's ability swallow whole pill . Documented malabsorption problem .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Endocrine Therapy</keyword>
</DOC>